NextDocs scoops up $5M; Signal Genetics highlights independent study of algorithms for breast cancer prognoses;

> NextDocs, a provider of data management for drug developers, scooped up $5 million in a round of financing after grabbing a $10 million round of growth equity from OpenView Venture Partners two years ago. Item

> Signal Genetics touted results from a Weill Cornell study of its algorithms for providing prognoses for cases of breast cancer. Release

> Here's a case study of Merck's ($MRK) use of an electronic lab notebook from PerkinElmer. Item

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.